WELCOME TO The Biotechnology REPORT
Applied Biological Materials - abm
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
European Biotechnology | February 17, 2020
PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). The PDUFA date was set for August 16, 2020 by the US Food and Drug Administration (FDA) for lurbinectedin as second-line treatment for patients with SCLC who relapsed following platium-based chemotherapy. The synthetic drug developed by PharmaMar SA (Madrid, Spain) and exclusively licenced by Jazz Pharmaceuticals plc (Dublin, Ireland) in December 2019 works b...
Phylagen | July 31, 2020
Phylagen, an award-winning biotech company specializing in decoding the environmental microbiome for indoor safety, today announced the national availability of its Phylagen Surface™ SARS-CoV-2 (COVID-19) test kit. Designed to be used by anyone on any surface, Phylagen Surface™ provides an early indication of outbreaks in shared spaces including nursing homes, schools, hospitals, restaurants, offices and retail shops."Surface testing can help curb the spread of COVID-19 bu...
Zivo | June 28, 2022
ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022.
Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and gr...
BioSpace | April 02, 2020
Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. Rounding out the series seed syndicate are two additional investors, Kaitai Capital and Legend Star Fund. The company has assembled a world-class team of small-molecule drug developers and an exceptional Scientific A...
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE